About Ascendance Biotechnology
Ascendance Biotechnology is a Healthcare company based in Medford (United States) founded in 2015, and was acquired by BioIVT in March 2018. Micro-liver cell-based platforms for use in safety testing, and pharmaceutical, biotherapeutic, and diagnostic product development. Ascendance Biotechnology has raised $880 thousand across 2 funding rounds from investors including BioIVT. The company has 11 employees. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Ascendance Biotechnology was established in 2015 through the consolidation of assets from Hepregen Corporation and ESI BIO, operating as a transnational entity in the biotechnology sector. Cell-based assay products, including HepatoPac and HepatoMune micro-liver platforms, are manufactured in Medford, United States, alongside contract services for pharmaceutical and diagnostic applications. Stem cell lines, progenitor cells, hydrogel kits, antibodies, and small molecules from the ESI BIO line are also distributed.
- Headquarters Medford, United States
- Employees 11
- Stage Acquired
- SectorsHealthcare
- Website ascendancebio.com
- Acquired by BioIVT (Mar 2018)
Funding Insights of Ascendance Biotechnology
Ascendance Biotechnology has successfully raised a total of $880K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $230 thousand completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $880,000
- Total Rounds 2
- Last Round Seed — $230,000
- First Round $650,000
(Dec 2015)
All 2 funding rounds of Ascendance Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2016 | $230,000 | Seed | – | – | – |
| Dec 2015 | $650,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Ascendance Biotechnology
Ascendance Biotechnology has secured backing from 1 investor. Prominent investors backing the company include BioIVT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of in vitro diagnostic products and assay services | 2015 | bioivt.com | Westbury, United States |
Investor details for Ascendance Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ascendance Biotechnology
4 dated milestones of Ascendance Biotechnology across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Ascendance Biotechnology is founded.
- Funding First funding round of $650K.
- Funding Latest funding round, Seed, of $230K.
- Exit Acquired by BioIVT.
Competitors of Ascendance Biotechnology
Ascendance Biotechnology has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Ascendance Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Ascendance Biotechnology (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ascendance Biotechnology
Complete news archive for Ascendance Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascendance Biotechnology
Ascendance Biotechnology was founded in 2015.
Ascendance Biotechnology is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Ascendance Biotechnology is a funded company, having raised a total of $880K across 2 funding rounds to date. The company's 1st funding round was a Seed of $650K, raised on Dec 2015.
Ascendance Biotechnology has 11 employees.
Ascendance Biotechnology was established in 2015 through the consolidation of assets from Hepregen Corporation and ESI BIO, operating as a transnational entity in the biotechnology sector. Cell-based assay products, including HepatoPac and HepatoMune micro-liver platforms, are manufactured in Medford, United States, alongside contract services for pharmaceutical and diagnostic applications. Stem cell lines, progenitor cells, hydrogel kits, antibodies, and small molecules from the ESI BIO line are also distributed.
Ascendance Biotechnology's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Ascendance Biotechnology has 1 investor. Key investors include BioIVT.
Yes. Ascendance Biotechnology was acquired by BioIVT in March 2018.